What is Sonoma Pharmaceu's earnings per share (EPS)?

Sonoma Pharmaceu (SNOA) reported diluted earnings per share of $-1.89 for fiscal year 2026. This represents a 32.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sonoma Pharmaceu Financials

SNOA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE March

This page shows Sonoma Pharmaceu (SNOA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SNOA FY2025 2026-06-16

Loss reduction is coming from leaner operations and near-cash break-even, but liquidity still relies on outside funding.

From FY2023 to FY2025, operating cash burn shrank from -$6.2M to -$88K, which means the operating model moved close to funding itself even before GAAP profit arrived. Yet FY2025 cash of $5.4M was also helped by financing inflows of $3.0M, so the business is improving operationally while still depending on capital raises to rebuild liquidity.

The improvement in losses looks more like cost discipline than a demand breakout: revenue stayed in the same small band, but gross margin reached 38.3% as SG&A kept easing. R&D remained near $1.8M, suggesting management trimmed overhead rather than broadly pulling back on operating investment.

Near-term obligations appear manageable because the current ratio stayed around 3.1x, giving the company working-capital breathing room. The weaker point is the equity cushion: liabilities of $9.3M are more than double equity of $4.4M, so balance-sheet flexibility remains limited despite better cash burn.

Financial Health Signals

Financial Health Score 38/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sonoma Pharmaceu's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-18.38

Sonoma Pharmaceu scores -18.38, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.0M) relative to total liabilities ($10.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Sonoma Pharmaceu passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.24x

For every $1 of reported earnings, Sonoma Pharmaceu generates $1.24 in operating cash flow (-$3.9M OCF vs -$3.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$19.5M

YoY+36.7%

5Y CAGR+0.9%

10Y CAGR+7.6%

Sonoma Pharmaceu generated $19.5M in revenue in fiscal year 2026. This represents an increase of 36.7% from the prior year.

EBITDA

-$2.3M

YoY+35.0%

Sonoma Pharmaceu's EBITDA was -$2.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 35.0% from the prior year.

Net Income

-$3.2M

YoY+8.2%

Sonoma Pharmaceu reported -$3.2M in net income in fiscal year 2026. This represents an increase of 8.2% from the prior year.

EPS (Diluted)

$-1.89

YoY+32.3%

Sonoma Pharmaceu earned $-1.89 per diluted share (EPS) in fiscal year 2026. This represents an increase of 32.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.1M

YoY-2355.4%

Sonoma Pharmaceu generated -$4.1M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 2355.4% from the prior year.

Cash & Debt

$2.4M

YoY-55.4%

5Y CAGR-10.7%

10Y CAGR-10.7%

Sonoma Pharmaceu held $2.4M in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

YoY+10.1%

Sonoma Pharmaceu had 2M shares outstanding in fiscal year 2026. This represents an increase of 10.1% from the prior year.

Margins & Returns

Gross Margin

38.0%

YoY-0.3pp

5Y CAGR+2.8pp

10Y CAGR+9.7pp

Sonoma Pharmaceu's gross margin was 38.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

-12.6%

YoY+13.4pp

5Y CAGR+5.9pp

10Y CAGR+144.5pp

Sonoma Pharmaceu's operating margin was -12.6% in fiscal year 2026, reflecting core business profitability. This is up 13.4 percentage points from the prior year.

Net Margin

-16.3%

YoY+7.9pp

5Y CAGR+4.9pp

10Y CAGR+92.2pp

Sonoma Pharmaceu's net profit margin was -16.3% in fiscal year 2026, showing the share of revenue converted to profit. This is up 7.9 percentage points from the prior year.

Return on Equity

-102.6%

YoY-24.2pp

5Y CAGR-28.9pp

10Y CAGR-2.4pp

Sonoma Pharmaceu's ROE was -102.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 24.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.3M

YoY+25.2%

5Y CAGR+32.6%

10Y CAGR+2.3%

Sonoma Pharmaceu invested $2.3M in research and development in fiscal year 2026. This represents an increase of 25.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$192K

YoY+140.0%

5Y CAGR+1.4%

10Y CAGR-5.7%

Sonoma Pharmaceu invested $192K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 140.0% from the prior year.

SNOA Income Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Revenue	$19.5M+36.7%	$14.3M+12.2%	$12.7M-4.0%	$13.3M+5.1%	$12.6M-32.2%	$18.6M
Cost of Revenue	$12.1M+37.3%	$8.8M+10.4%	$8.0M-9.2%	$8.8M+1.9%	$8.6M-28.5%	$12.1M
Gross Profit	$7.4M+35.7%	$5.5M+15.2%	$4.7M+6.0%	$4.5M+12.1%	$4.0M-39.1%	$6.6M
R&D Expenses	$2.3M+25.2%	$1.8M-3.0%	$1.9M+803.9%	$207K+65.6%	$125K-77.5%	$555K
SG&A Expenses	$7.6M+3.3%	$7.4M-2.8%	$7.6M-14.3%	$8.8M-9.4%	$9.8M+3.2%	$9.5M
Operating Income	-$2.5M+33.7%	-$3.7M+21.1%	-$4.7M-2.9%	-$4.6M+22.4%	-$5.9M-70.7%	-$3.4M
Interest Expense	N/A	N/A	N/A	$16K+260.0%	-$10K-183.3%	$12K
Income Tax	-$244K-144.4%	$550K+380.6%	-$196K-493.9%	-$33K+90.1%	-$332K-146.6%	$713K
Net Income	-$3.2M+8.2%	-$3.5M+28.5%	-$4.8M+6.1%	-$5.2M-1.3%	-$5.1M-28.8%	-$4.0M
EPS (Diluted)	$-1.89+32.3%	$-2.79+73.8%	$-10.63	$-1.52+20.8%	$-1.92	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$5.6M+27.9%	$4.3M-22.4%	$5.6M+39.6%	$4.0M+7.0%	$3.8M+5.3%	$3.6M-0.4%	$3.6M+5.5%	$3.4M
Cost of Revenue	$3.4M+25.2%	$2.7M-22.5%	$3.5M+36.6%	$2.6M+14.6%	$2.2M-3.0%	$2.3M+3.4%	$2.2M+6.4%	$2.1M
Gross Profit	$2.2M+32.2%	$1.6M-22.2%	$2.1M+44.8%	$1.5M-4.2%	$1.5M+20.3%	$1.3M-6.7%	$1.4M+4.2%	$1.3M
R&D Expenses	$545K-2.2%	$557K-3.1%	$575K-3.2%	$594K+44.5%	$411K-3.7%	$427K-15.6%	$506K+7.7%	$470K
SG&A Expenses	$2.0M+12.2%	$1.8M-5.9%	$1.9M-4.2%	$2.0M+10.8%	$1.8M-5.4%	$1.9M+9.9%	$1.7M-15.1%	$2.0M
Operating Income	-$351K+48.2%	-$678K-101.2%	-$337K+69.2%	-$1.1M-66.9%	-$656K+36.4%	-$1.0M-21.3%	-$850K+27.5%	-$1.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$84K+164.6%	-$130K+34.0%	-$197K-19600.0%	-$1K-100.4%	$248K+2655.6%	$9K-93.9%	$147K+0.7%	$146K
Net Income	-$581K+29.1%	-$819K-53.4%	-$534K+57.0%	-$1.2M-59.9%	-$776K+16.4%	-$928K-52.1%	-$610K+46.6%	-$1.1M
EPS (Diluted)	N/A	$-0.48-50.0%	$-0.32+57.9%	$-0.76	N/A	$-0.63-6.8%	$-0.59	$-1.34

SNOA Balance Sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Total Assets	$14.0M+1.9%	$13.7M-7.1%	$14.7M-9.2%	$16.2M-13.9%	$18.8M+25.7%	$15.0M
Current Assets	$12.1M-4.3%	$12.6M+0.8%	$12.5M-9.1%	$13.8M-16.0%	$16.4M+26.6%	$13.0M
Cash & Equivalents	$2.4M-55.4%	$5.4M+71.8%	$3.1M-18.1%	$3.8M-48.4%	$7.4M+75.3%	$4.2M
Inventory	$3.7M+25.2%	$2.9M+7.2%	$2.7M-4.9%	$2.9M+7.3%	$2.7M+5.3%	$2.5M
Accounts Receivable	$2.5M+13.2%	$2.2M-23.0%	$2.9M+12.7%	$2.6M+6.9%	$2.4M-14.2%	$2.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.9M+17.1%	$9.3M+7.9%	$8.6M+4.2%	$8.3M-18.7%	$10.1M+5.4%	$9.6M
Current Liabilities	$4.8M+18.0%	$4.1M+10.1%	$3.7M+0.1%	$3.7M-36.1%	$5.8M+42.7%	$4.1M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$1.3M
Total Equity	$3.1M-29.8%	$4.4M-28.1%	$6.1M-23.1%	$8.0M-8.3%	$8.7M+62.2%	$5.4M
Retained Earnings	-$201.0M-1.6%	-$197.8M-1.8%	-$194.3M-2.6%	-$189.5M-2.8%	-$184.4M-2.8%	-$179.3M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$14.0M+2.5%	$13.6M-1.7%	$13.9M-5.1%	$14.6M+6.6%	$13.7M+0.2%	$13.7M-0.1%	$13.7M+0.1%	$13.7M
Current Assets	$12.1M-0.4%	$12.1M-2.8%	$12.5M-4.6%	$13.1M+3.6%	$12.6M+2.2%	$12.4M+1.3%	$12.2M+2.5%	$11.9M
Cash & Equivalents	$2.4M-6.3%	$2.6M-15.6%	$3.0M-15.8%	$3.6M-32.9%	$5.4M+2.6%	$5.2M+28.4%	$4.1M+57.5%	$2.6M
Inventory	$3.7M-1.4%	$3.7M+1.9%	$3.6M-4.4%	$3.8M+30.4%	$2.9M-7.3%	$3.1M+10.8%	$2.8M+6.7%	$2.7M
Accounts Receivable	$2.5M+6.1%	$2.4M-11.9%	$2.7M+3.9%	$2.6M+16.6%	$2.2M-7.2%	$2.4M-23.8%	$3.2M-2.8%	$3.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.9M+6.6%	$10.2M+1.2%	$10.1M-4.5%	$10.5M+13.5%	$9.3M+5.5%	$8.8M+5.6%	$8.3M-4.2%	$8.7M
Current Liabilities	$4.8M+14.6%	$4.2M-2.4%	$4.3M-10.8%	$4.8M+18.4%	$4.1M+10.6%	$3.7M+11.9%	$3.3M-11.8%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.1M-9.8%	$3.4M-9.4%	$3.8M-6.6%	$4.1M-8.0%	$4.4M-9.4%	$4.9M-9.0%	$5.4M+7.6%	$5.0M
Retained Earnings	-$201.0M-0.3%	-$200.4M-0.4%	-$199.6M-0.3%	-$199.0M-0.6%	-$197.8M-0.4%	-$197.0M-0.5%	-$196.1M-0.3%	-$195.5M

SNOA Cash Flow Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$3.9M-4369.3%	-$88K+96.3%	-$2.4M+61.0%	-$6.2M-44.8%	-$4.2M-25.8%	-$3.4M
Capital Expenditures	$192K+140.0%	$80K+3900.0%	$2K-99.3%	$269K+96.4%	$137K-23.5%	$179K
Free Cash Flow	-$4.1M-2355.4%	-$168K+93.0%	-$2.4M+62.6%	-$6.4M-46.4%	-$4.4M-23.3%	-$3.6M
Investing Cash Flow	-$192K-140.0%	-$80K-3900.0%	-$2K+99.2%	-$258K-160.6%	-$99K-125.5%	$388K
Financing Cash Flow	$477K-84.3%	$3.0M+80.8%	$1.7M-32.7%	$2.5M-66.3%	$7.4M+123.6%	$3.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$519K+32.1%	-$764K-20.3%	-$635K+68.5%	-$2.0M-2021.1%	-$95K-116.8%	$565K+59.6%	$354K+138.8%	-$912K
Capital Expenditures	$29K-38.3%	$47K+370.0%	$10K-90.6%	$106K+125.5%	$47K+2250.0%	$2K-92.3%	$26K+420.0%	$5K
Free Cash Flow	-$548K+32.4%	-$811K-25.7%	-$645K+69.6%	-$2.1M-1393.7%	-$142K-125.2%	$563K+71.6%	$328K+135.8%	-$917K
Investing Cash Flow	-$29K+38.3%	-$47K-370.0%	-$10K+90.6%	-$106K-125.5%	-$47K-2250.0%	-$2K+92.3%	-$26K-420.0%	-$5K
Financing Cash Flow	$387K+84.3%	$210K+438.7%	-$62K-6.9%	-$58K-124.0%	$242K-65.8%	$708K-51.0%	$1.4M+127.0%	$636K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SNOA Financial Ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Gross Margin	38.0%-0.3pp	38.3%+1.0pp	37.3%+3.5pp	33.7%+2.1pp	31.6%-3.6pp	35.2%
Operating Margin	-12.6%+13.4pp	-26.0%+10.9pp	-36.9%-2.5pp	-34.4%+12.2pp	-46.6%-28.1pp	-18.5%
Net Margin	-16.3%+7.9pp	-24.2%+13.8pp	-38.0%+0.8pp	-38.8%+1.5pp	-40.3%-19.1pp	-21.2%
Return on Equity	-102.6%-24.2pp	-78.4%+0.4pp	-78.8%-14.2pp	-64.6%-6.1pp	-58.5%+15.2pp	-73.7%
Return on Assets	-22.7%+2.5pp	-25.3%+7.6pp	-32.8%-1.1pp	-31.7%-4.8pp	-27.0%-0.6pp	-26.4%
Current Ratio	2.50-0.6	3.09-0.3	3.37-0.3	3.71+0.9	2.82-0.4	3.18
Debt-to-Equity	3.51+1.4	2.10+0.7	1.40+0.4	1.03+1.0	0.00-0.2	0.24
FCF Margin	-21.1%-19.9pp	-1.2%+17.7pp	-18.9%+29.5pp	-48.4%-13.7pp	-34.7%-15.6pp	-19.1%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	39.2%+1.3pp	37.9%+0.1pp	37.8%+1.4pp	36.5%-4.2pp	40.7%+5.1pp	35.6%-2.4pp	38.0%-0.5pp	38.5%
Operating Margin	-6.3%+9.3pp	-15.6%-9.6pp	-6.0%+21.3pp	-27.3%-9.8pp	-17.5%+11.5pp	-28.9%-5.2pp	-23.8%+10.8pp	-34.6%
Net Margin	-10.4%+8.4pp	-18.8%-9.3pp	-9.5%+21.4pp	-30.9%-10.2pp	-20.7%+5.4pp	-26.0%-9.0pp	-17.0%+16.7pp	-33.7%
Return on Equity	-18.8%+5.1pp	-23.9%-9.8pp	-14.1%+16.5pp	-30.6%-13.0pp	-17.6%+1.5pp	-19.1%-7.7pp	-11.4%+11.6pp	-23.0%
Return on Assets	-4.2%+1.9pp	-6.0%-2.2pp	-3.9%+4.7pp	-8.5%-2.8pp	-5.7%+1.1pp	-6.8%-2.3pp	-4.5%+3.9pp	-8.4%
Current Ratio	2.50-0.4	2.88-0.0	2.89+0.2	2.70-0.4	3.09-0.3	3.34-0.4	3.69+0.5	3.18
Debt-to-Equity	3.51+0.5	2.97+0.3	2.66+0.1	2.60+0.5	2.10+0.3	1.81+0.2	1.56-0.2	1.75
FCF Margin	-9.8%+8.8pp	-18.6%-7.1pp	-11.5%+41.3pp	-52.8%-49.0pp	-3.8%-19.6pp	15.8%+6.6pp	9.2%+36.2pp	-27.0%

Similar Companies

Evoke Pharma Inc EVOK

$18.9M

Sunshine Biopharma Inc SBFM

$4.5M

Biofrontera Inc BFRI

$14.6M

Cbdmd Inc YCBD

$8.5M

Im Cannabis Corp IMCC

$1.5M

Frequently Asked Questions

What is Sonoma Pharmaceu's annual revenue?

Sonoma Pharmaceu (SNOA) reported $19.5M in total revenue for fiscal year 2026. This represents a 36.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sonoma Pharmaceu's revenue growing?

Sonoma Pharmaceu (SNOA) revenue grew by 36.7% year-over-year, from $14.3M to $19.5M in fiscal year 2026.

Is Sonoma Pharmaceu profitable?

No, Sonoma Pharmaceu (SNOA) reported a net income of -$3.2M in fiscal year 2026, with a net profit margin of -16.3%.

What is Sonoma Pharmaceu's EBITDA?

Sonoma Pharmaceu (SNOA) had EBITDA of -$2.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sonoma Pharmaceu's gross margin?

Sonoma Pharmaceu (SNOA) had a gross margin of 38.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sonoma Pharmaceu's operating margin?

Sonoma Pharmaceu (SNOA) had an operating margin of -12.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Sonoma Pharmaceu's net profit margin?

Sonoma Pharmaceu (SNOA) had a net profit margin of -16.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Sonoma Pharmaceu's return on equity (ROE)?

Sonoma Pharmaceu (SNOA) has a return on equity of -102.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Sonoma Pharmaceu's free cash flow?

Sonoma Pharmaceu (SNOA) generated -$4.1M in free cash flow during fiscal year 2026. This represents a -2355.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sonoma Pharmaceu's operating cash flow?

Sonoma Pharmaceu (SNOA) generated -$3.9M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Sonoma Pharmaceu's total assets?

Sonoma Pharmaceu (SNOA) had $14.0M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Sonoma Pharmaceu's capital expenditures?

Sonoma Pharmaceu (SNOA) invested $192K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Sonoma Pharmaceu spend on research and development?

Sonoma Pharmaceu (SNOA) invested $2.3M in research and development during fiscal year 2026.

How many shares does Sonoma Pharmaceu have outstanding?

Sonoma Pharmaceu (SNOA) had 2M shares outstanding as of fiscal year 2026.

What is Sonoma Pharmaceu's current ratio?

Sonoma Pharmaceu (SNOA) had a current ratio of 2.50 as of fiscal year 2026, which is generally considered healthy.

What is Sonoma Pharmaceu's debt-to-equity ratio?

Sonoma Pharmaceu (SNOA) had a debt-to-equity ratio of 3.51 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sonoma Pharmaceu's return on assets (ROA)?

Sonoma Pharmaceu (SNOA) had a return on assets of -22.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Sonoma Pharmaceu's cash runway?

Based on fiscal year 2026 data, Sonoma Pharmaceu (SNOA) had $2.4M in cash against an annual operating cash burn of $3.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sonoma Pharmaceu's Altman Z-Score?

Sonoma Pharmaceu (SNOA) has an Altman Z-Score of -18.38, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sonoma Pharmaceu's Piotroski F-Score?

Sonoma Pharmaceu (SNOA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sonoma Pharmaceu's earnings high quality?

Sonoma Pharmaceu (SNOA) has an earnings quality ratio of 1.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sonoma Pharmaceu?

Sonoma Pharmaceu (SNOA) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.